Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sibeprenlimab by Visterra for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Otsuka's Sibeprenlimab?
Sibeprenlimab is a monoclonal antibody commercialized by Otsuka, with a leading Phase III program in IgA Nephropathy (Berger's Disease). According...
Sibeprenlimab by Visterra for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease). According to GlobalData,...